Global Pharmatech, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GBLP research report →
Companywww.globalpharmatech.com
Global Pharmatech, Inc. engages in the research, production, and development of herbal medicine, bio-medicine, chemical medicine, traditional chinese medicine, and dietary supplements primarily in China. The company's principal product line consists of XS CAPSULE (XIN-SHU) for the treatment of angina and other coronary disease; JUTAI SOFT CAPSULE, a dietary supplement; QINGXUAN ANTI-HYPERTENSION TABLET, an over-the-counter drug product indicated for the treatment of hypertension and high serum cholesterol level; and YANREQING TABLET for the treatment of inflammation.
- CEO
- Meisheng Liao
- IPO
- 2002
- Employees
- 217
- HQ
- Changchun, CN
Price Chart
Valuation
- Market Cap
- $20.76M
- P/E
- 667.31
- P/S
- 50.48
- P/B
- -2291.96
- EV/EBITDA
- 485.38
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 25.46%
- Op Margin
- 5.18%
- Net Margin
- 7.57%
- ROE
- -48.47%
- ROIC
- 26.13%
Growth & Income
- Revenue
- $310.89K · 368.39%
- Net Income
- $-67,728 · 51.10%
- EPS
- $-0.00 · 50.00%
- Op Income
- $-67,815
- FCF YoY
- 0.00%
Performance & Tape
- 52W High
- $0.20
- 52W Low
- $0.05
- 50D MA
- $0.05
- 200D MA
- $0.05
- Beta
- 0.27
- Avg Volume
- 1.66K
Get TickerSpark's AI analysis on GBLP
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our GBLP Coverage
We haven't published any research on GBLP yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate GBLP Report →